2 / 23
Page 10
Notes:
allied
academies
Asian Journal of Biomedical and Pharmaceutical Sciences | Volume 8
March 26-27, 2018 | Orlando, USA
World Summit on
Healthcare & Hospital Management
&
International Conference & Exhibition on
Biologics and Biosimilars
M
any monoclonal antibody biosimilar products are coming
on the market since the world first mAb biosimilar,
which was Infliximab biosimilar, was approved by EMA and
commercialized in 2013. In the beginning of commercialization,
there has been lots of resistance from Healthcare Professionals
(HCPs) mainly because of their concerns about efficacy and
safety. In particular, many HCPs wanted to see more data
about the immunogenicity and other side effect profiles. Now,
market accessibility of mAb biosimilars has been improved a lot
and potential concerns of HCP communities are substantially
reducing because much more data about efficacy and side
effects including immunogenicity of biosimilar products became
available from real world experience as well as additional
clinical trials. In terms of pharmacoeconomics, actually huge
amount of healthcare budget can be saved from using mAb
biosimilars and then the saved budget can be used for the
biologic treatment of muchmore patients and supporting other
stakeholders. In another words, the benefit frombiosimilars can
be distributed back to HCPs. The agenda of this presentation
will be development of biosimilars including quality, market
accessibility and their pharmacoeconomics.
Speaker Biography
Stanley Hong is a Senior Adviser at the Celltrion Healthcare and has played an
important part in its development and success. He was the President of Research and
Development at Celltrion, Inc., where he was responsible for the entire R&D including
product discovery as well as biosimilar development. His team led the successful
development of REMSIMA™, the world’s first biosimilar, and gained approval for the
product in Korea, Japan, Canada, European Union and USFDA. He was also responsible
for the development of other biosimilars in Celltrion and has presented data on
biosimilars at national and international medical meetings. He was also the President
and CEO of Celltrion Healthcare.
e:
seungsuh.hong@celltrion.comStanley Hong
Celltrion Healthcare, South Korea
Market uptake of mAb biosimilars and their pharmacoeconomics